BGM1812

DRUG2 trials

Sponsors

BrightGene Bio-Medical Technology Co., Ltd.

Conditions

HealhtyOverweight or Obesity

Phase 1

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and Women

RecruitingNCT07224399

BrightGene Bio-Medical Technology Co., Ltd.Healhty, Overweight or Obesity

Start: 2025-10-09End: 2026-05-15Target: 60Updated: 2025-11-06

A Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese Participants

RecruitingNCT07294235

BrightGene Bio-Medical Technology Co., Ltd.Overweight or Obesity

Start: 2025-12-05End: 2026-03-02Target: 60Updated: 2025-12-19